As serum levels of PLT-EVs strongly associated with severity of SARS-CoV-2 infection [19] and thromboemboli contribute to the morbidity of post-acute sequelae of COVID (PASC) [9], CLEC5A and TLR2 are promising therapeutic targets to attenuate thromboinflammation and reduce the risk of post-acute COVID-19 syndrome in the future. Here, CLEC5A is linked to long COVID-19.